Salud financiera de hoja de balance de Jubilant Pharmova
Salud financiera controles de criterios 3/6
Jubilant Pharmova tiene un patrimonio de accionistas total de ₹54.2B y una deuda total de ₹34.1B, lo que sitúa su ratio deuda-patrimonio en 63%. Sus activos y pasivos totales son ₹115.5B y ₹61.3B respectivamente. El BAIT de Jubilant Pharmova es de ₹5.2B, por lo que su ratio de cobertura de intereses es de 1.9. Tiene efectivo e inversiones a corto plazo que ascienden a ₹9.6B.
Información clave
67.6%
Ratio deuda-patrimonio
₹36.64b
Deuda
| Ratio de cobertura de intereses | 2.1x |
| Efectivo | ₹9.57b |
| Patrimonio | ₹54.21b |
| Total pasivo | ₹61.27b |
| Activos totales | ₹115.49b |
Actualizaciones recientes sobre salud financiera
Jubilant Pharmova (NSE:JUBLPHARMA) Has A Somewhat Strained Balance Sheet
Jul 13
Jubilant Pharmova (NSE:JUBLPHARMA) Has A Somewhat Strained Balance Sheet
Mar 14These 4 Measures Indicate That Jubilant Pharmova (NSE:JUBLPHARMA) Is Using Debt Extensively
Dec 02These 4 Measures Indicate That Jubilant Pharmova (NSE:JUBLPHARMA) Is Using Debt Extensively
Jul 26Is Jubilant Pharmova (NSE:JUBLPHARMA) A Risky Investment?
Dec 10Does Jubilant Pharmova (NSE:JUBLPHARMA) Have A Healthy Balance Sheet?
Jun 15Recent updates
Jubilant Pharmova Limited (NSE:JUBLPHARMA) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Aug 24Jubilant Pharmova (NSE:JUBLPHARMA) Has A Somewhat Strained Balance Sheet
Jul 13Jubilant Pharmova (NSE:JUBLPHARMA) Has A Somewhat Strained Balance Sheet
Mar 14Jubilant Pharmova Limited (NSE:JUBLPHARMA) Shares Fly 27% But Investors Aren't Buying For Growth
Dec 23These 4 Measures Indicate That Jubilant Pharmova (NSE:JUBLPHARMA) Is Using Debt Extensively
Dec 02These 4 Measures Indicate That Jubilant Pharmova (NSE:JUBLPHARMA) Is Using Debt Extensively
Jul 26Estimating The Fair Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)
May 11Is Jubilant Pharmova (NSE:JUBLPHARMA) A Risky Investment?
Dec 10Jubilant Pharmova (NSE:JUBLPHARMA) Has Announced A Dividend Of ₹5.00
Aug 01Does Jubilant Pharmova (NSE:JUBLPHARMA) Have A Healthy Balance Sheet?
Jun 15Calculating The Intrinsic Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)
Mar 22Is Jubilant Pharmova (NSE:JUBLPHARMA) A Risky Investment?
Feb 15Calculating The Intrinsic Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)
Dec 20Here's Why It's Unlikely That Jubilant Pharmova Limited's (NSE:JUBLPHARMA) CEO Will See A Pay Rise This Year
Sep 15Here's Why Jubilant Pharmova (NSE:JUBLPHARMA) Can Manage Its Debt Responsibly
Aug 21Time To Worry? Analysts Are Downgrading Their Jubilant Pharmova Limited (NSE:JUBLPHARMA) Outlook
Jun 08An Intrinsic Calculation For Jubilant Pharmova Limited (NSE:JUBLPHARMA) Suggests It's 39% Undervalued
May 25Analysts Just Made A Major Revision To Their Jubilant Pharmova Limited (NSE:JUBILANT) Revenue Forecasts
Feb 10Estimating The Fair Value Of Jubilant Pharmova Limited (NSE:JUBILANT)
Feb 08
Shareholders Are Thrilled That The Jubilant Life Sciences (NSE:JUBILANT) Share Price Increased 217%
Jan 11Does Jubilant Life Sciences' (NSE:JUBILANT) CEO Salary Compare Well With Industry Peers?
Dec 31Read This Before Selling Jubilant Life Sciences Limited (NSE:JUBILANT) Shares
Dec 20Has Jubilant Life Sciences Limited's (NSE:JUBILANT) Impressive Stock Performance Got Anything to Do With Its Fundamentals?
Dec 08We Think Jubilant Life Sciences (NSE:JUBILANT) Can Stay On Top Of Its Debt
Nov 27Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo (₹38.8B) de JUBLPHARMA superan a sus pasivos a corto plazo (₹18.9B).
Pasivo a largo plazo: Los activos a corto plazo (₹38.8B) de JUBLPHARMA no cubren sus pasivos a largo plazo (₹42.4B).
Historial y análisis de deuda-patrimonio
Nivel de deuda: La relación deuda neta-capital de JUBLPHARMA (45.3%) se considera alta.
Reducción de la deuda: El ratio deuda-patrimonio de JUBLPHARMA ha pasado de 100.2% a 63% en los últimos 5 años.
Cobertura de la deuda: La deuda de JUBLPHARMA está bien cubierta por el flujo de caja operativo (28.4%).
Cobertura de intereses: Los pagos de intereses de la deuda de JUBLPHARMA no están bien cubiertos por el BAIT (1.9x cobertura).